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Abstract
Background: There is a growing interest in the use of 18F-FDG PET-CT to monitor tuberculosis (TB) treatment
response. However, TB causes complex and widespread pathology, which is challenging to segment and quantify
in a reproducible manner.
To address this, we developed a technique to standardise uptake (Z-score), segment and quantify tuberculous lung
lesions on PET and CT concurrently, in order to track changes over time. We used open source tools and created a
MATLAB script. The technique was optimised on a training set of five pulmonary tuberculosis (PTB) cases after
standard TB therapy and 15 control patients with lesion-free lungs.
Results: We compared the proposed method to a fixed threshold (SUV > 1) and manual segmentation by two readers
and piloted the technique successfully on scans of five control patients and five PTB cases (four cured and one failed
treatment case), at diagnosis and after 1 and 6 months of treatment. There was a better correlation between the
Z-score-based segmentation and manual segmentation than SUV > 1 and manual segmentation in terms of
overall spatial overlap (measured in Dice similarity coefficient) and specificity (1 minus false positive volume fraction).
However, SUV > 1 segmentation appeared more sensitive. Both the Z-score and SUV > 1 showed very low variability
when measuring change over time. In addition, total glycolytic activity, calculated using segmentation by Z-score and
lesion-to-background ratio, correlated well with traditional total glycolytic activity calculations. The technique quantified
various PET and CT parameters, including the total glycolytic activity index, metabolic lesion volume, lesion volumes at
different CT densities and combined PET and CT parameters. The quantified metrics showed a marked decrease in the
cured cases, with changes already apparent at month one, but remained largely unchanged in the failed treatment case.
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Conclusions: Our technique is promising to segment and quantify the lung scans of pulmonary tuberculosis patients in a
semi-automatic manner, appropriate for measuring treatment response. Further validation is required in larger cohorts.
Keywords: 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography, Tuberculosis,
Image analysis, Lesion segmentation, Lesion quantification
Background
Positron emission tomography/computerised tomog-
raphy (PET-CT) is well established in the diagnostic
workup, treatment planning and response assessment of
cancer and various inflammatory and infectious diseases
[1, 2]. The most commonly used PET tracer is 18F-fluor-
odeoxyglucose (FDG). It reflects glucose metabolism and
shows increased uptake in areas of inflammation. PET
scanners measure the radiopharmaceutical concentration
in tissue [3–5].
Uptake intensity in tissue is variable and influenced by
numerous patient-, timing- and equipment factors,
which is why the lesion-to-background ratio is often
considered a more robust measure than absolute uptake
[6]. Several semi-quantitative measurements of PET
voxel intensity have been developed, of which standar-
dised uptake value (SUV), is most commonly used. It
compensates for variation in body size, injected activity
and radioactive decay.
The metabolic lesion volume (MLV), maximum and
mean SUV within the lesion (SUVmax and SUVmean) and
the total glycolytic activity (TGA = MLV × SUVmean) are
the PET parameters most commonly used for lesion
quantification [3, 4, 7–9].
The borders of the MLV can be delineated visually or
using various semi-automated techniques, however no
single technique has proven optimal for all applications
[6]. In most cases lesion delineation is still performed
manually, based on visual interpretation of PET or CT im-
ages. This is prone to inter- and intra-operator variation,
especially for PET due to its lower spatial resolution and
inherent noise [8–15]. Multiple methods are used and
proposed to decrease variation in lesion segmentation.
These include using reference values to normalise the
lesion- to- background uptake intensity by comparison to
liver or mediastinal blood pool uptake [16–18] and the
use of automated segmentation techniques. Automated
segmentation techniques include thresholding techniques,
gradient-based techniques and stochastic- and
learning-based computerised methods [6]. Thresholds
may be fixed or adaptive. Adaptive thresholds utilises
image parameters, such as lesion-to-background ratio,
mean background intensity and estimated lesion intensity
in algorithms to define the threshold.
Some studies also focused on the quantification of im-
ages from CT scanners, which measure the density of
anatomical structures and lesions in Hounsfield units
(HU). It is not a functional scan and is less prone to
interscan variability. Only a few studies have evaluated
densometric quantification of CT scans in diffuse lung
disease; however, it appears to be reproducible and cor-
relate well with other disease markers [19–22]. Joint
segmentation of fused PET and CT images has shown
improved robustness compared to methods using only
data from PET [23].
The shortcomings of sputum culture to accurately in-
dicate when TB treatment has achieved sterilising cure
[24–26] escalate the cost to develop improved TB treat-
ment options. This has led to a growing interest to use
PET-CT imaging to monitor TB treatment response
[27–29]. In animal models, FDG PET-CT has been used
to accurately describe disease progression and response
to treatment in pulmonary tuberculosis (PTB) [30–35].
Human studies have also shown PET-CT of promise to
monitor the effect of treatment using simple descriptive
techniques [27, 31, 36–41]. We recently reported
PET-CT findings in PTB patients, before, during and
after therapy, and found strikingly complex and hetero-
geneous lesion responses [42].
Reproducible segmentation and quantification be-
comes particularly important in diseases with heteroge-
neous morphology, vague borders and multi-focal
distribution throughout an organ or system, such as TB
or sarcoidosis [31, 41] (example shown in Fig. 1). This is
especially important when accurate tracking of changes
over time is required. In most animal model PET-CT
studies, the authors used manual lesion delineation to
track changes throughout the lungs, or in individual
lesions [30–35]. Two separate human studies imple-
mented whole lung quantification of PET (using fixed
thresholds of SUV > 1 and SUV > 2, respectively) and
semi-quantitative CT reader scores [31, 41]. These found
that quantified PET images were more robust than
reader-based CT scores, and seemed to accurately meas-
ure changes in disease burden over time. To account for
the spatially complex lesions, two studies successfully
utilised computer-aided segmentation, respectively,
based on affinity propagation and both interactive region
growing and adaptive thresholding, in PET images of
TB-infected small animal models [43, 44].
In this report, we describe a semi-automated,
voxel-based technique developed for both PET and CT
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quantification to standardise and segment widespread
and heterogenous lesions throughout the lung and re-
producibly measure disease burden over time.
Methods
Study design
The method was optimised on a training set of 15
lesion-free lung scans obtained from patients undergoing
PET-CT scans for non-pulmonary clinical indications, as
well as scans from five PTB patients showing residual
lung lesions after treatment.
As a proof of concept, we applied the methodology to
quantify disease burden on an independent test set of
PET-CT scans from five controls and serial scans from
the first five patients participating in the PTB cohort
study, mentioned above [42]. The controls were from
the same communities (Cape Town, South-Africa), and
had contact with PTB patients, but were sputum culture
negative for Mycobacterium tuberculosis and had no
active lesions visible on PET-CT scan. PTB cases were
all diagnosed with drug-sensitive TB strains and were
HIV negative. Cases underwent scans at time-points
within 1 week from initiation of treatment (Dx), after
1 month of treatment (M1) and after 6 months of treat-
ment (M6), corresponding with the duration of standard
TB therapy. At the end of treatment, four of the PTB
cases were sputum culture negative and classified as
cured by healthcare providers in charge of treatment,
while one was still sputum culture positive and diag-
nosed as a failed treatment outcome. The study design is
summarised in Table 1.
PET-CT imaging
PET-CT scanning was performed with a Philips Gemini
Big Bore time-of-flight scanner according to internation-
ally accepted guidelines [45]. Patients fasted for 6 h
before FDG administration, but were encouraged to hy-
drate well. According to body weight, participants
received 185–259 MBq of 18F-FDG intravenously 60 min
before scan acquisition. PET images were reconstructed to
4 × 4 × 4 mm voxels using an iterative algorithm including
time-of-flight information and corrections for random
events, scatter, deadtime, attenuation and decay. The CT
scan parameters were set at 120 kV, 100 mAs, without
dose modulation with 1.17 × 1.17 mm pixels and a 3 mm
slice thickness.
Pre-processing
We exported images from the PET-CT workstation in
DICOM format and converted to ANALYSE file format
[46] using MRIConvert [47]. To ensure reproducibility
and facilitate direct comparison, we co-registered each
patient’s follow-up scans with the baseline CT, using
Statistical Parametric Mapping (SPM8) [48] with
MATLAB 2013b (Mathworks Inc.). During the
Fig. 1 3D rendered anterior view of fused 18F-FDG-PET-CT scan,
performed at diagnosis on a patient with sputum culture positive
pulmonary tuberculosis. It shows a wide distribution of lesions with
complex morphology, including a large cavity in the left upper lobe
with surrounding nodular infiltrates and patches of consolidation in
the left lower lobe
Table 1 Study design for method development and pilot application
Training set Test set
Group Negative controls Positive controls Negative controls PTB cases
n = 15 n = 5 n = 5 n = 5
PET-CT indication Clinical Observational cohort Observational cohort Observational cohort
Clinical background Diagnostic work-up PTB patients, after treatment PTB contacts PTB patients on treatment,
Scan time-points Single scan Single scan, after TB treatment Single scan Baseline, month 1 and
month 6 of treatment
Lung scan findings Lesion free Minimal to mild intensity
lesions after TB treatment
Lesion free Extensive lesions
Main function of inclusion Optimising Z-score
threshold specificity
Optimising Z-score
threshold sensitivity
Testing specificity Pilot application
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co-registration (using within-subject rigid-body model),
CT images were re-sliced to the voxel matrix of the cor-
responding PET scan (using trilinear interpolation). This
allowed direct voxel-based comparison of each patient’s
PET and CT images.
Lung masks for PET and CT
For each series of co-registered CT studies, we generated
a volume of interest (VOI) as a lung mask (Fig. 2a), in
MRICro version 1.39 [49] on overlaid CT images, using
the 3D region-growing, gradient-based tool. This
allowed setting the origin, radius and difference from
origin and edge gradient on the overlaid CT images. We
combined this with manual corrections, to avoid the ex-
clusion of dense lesions extending into the pleura from
the VOI. The lung mask excluded the lung hila and main
pulmonary vessels, but included smaller vessels. As a
final adjustment, we created a VOI of organs around the
lungs that included in the lung fields by misregistration
[usually the liver, spleen and mediastinum (Fig. 2b)],
with the region-growing tool on the PET scans, and then
deleted overlapping voxels from the lung mask. We con-
verted the mask to a binary image and filled any holes in
the mask, using ImageJ software [50] (Fig. 2c).
PET quantification: background reference
We selected two areas of normal lung parenchyma (NL)
as a reference VOI to standardise uptake in lung voxels
(Fig. 2d) [50]. Each NL volume consisted of spheres 15
to 25 mm in diameter that visually appeared lesion-free
on all co-registered scans. To enhance the representivity
of the sample, the spheres were selected in opposite
lungs or in some cases in different ipsilateral lobes,
depending on the distribution of lung pathology.
PET image quantification
We then quantified the pre-processed series of PET-CT
images, using a MATLAB script developed in-house.
The script quantified disease burden from the PET
images by assigning a Z-score to all voxel counts within
the lung mask based on the equation below:
Z ¼ counts−μNL
σNL
in which μNL and σNL are the mean and standard deviation
of PETcounts within the normal volume for each study.
The Z-score provided a statistical way to standardise
relative intensity of FDG uptake throughout the lungs. All
lung voxels exceeding a defined Z-score threshold were
defined as part of FDG-avid lesions. We then exported im-
ages of segmented lesion volumes to view alongside the
original images for visual quality assessment.
To determine the optimal Z-score threshold, we proc-
essed a set of 15 lesion-free lung scans with reiterations of
increasing Z-score thresholds, to minimise false positive
findings. As expected, at a low Z-score threshold, the vol-
umes segmented as abnormal in these healthy lungs were
high, but decreased to a value close to zero for Z ≥ 8
(Fig. 3). To minimise false negative findings, we also tested
increasing Z-score thresholds on scans that showed re-
sidual lesions with minimal or mild intensity and complex
morphology, obtained from five PTB patients after treat-
ment. Intensity was graded using an adaptation of the
Deauville classification [18, 42]. A threshold of Z = 8 delin-
eated all lesions with minimal FDG avidity, while Z = 9
Fig. 2 Example of volumes of interest (in red) required for quantification.
a Lung mask, on the combined CT images from baseline and follow-up
scans. b Volume of structures surrounding the lung affecting motion
misregistration (usually the mediastinum, liver and spleen) drawn on the
overlaid PET images. We then deleted overlapping areas on the lung
mask to leave only areas unaffected by misregistration. c Binary image
representing the final lung mask. d Reference volumes of normal lung
tissue, represented by two spheres in opposite lungs or ipsilateral lobes.
It is also drawn on the overlaid CT images, but viewed alongside the PET
images to ensure that it represents lesion-free lung
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delineated all lesions with mild FDG avidity, but failed to
detect some lesions with minimal FDG avidity (Fig. 4). We
thus chose a cut-off of Z = 8 based on its low false positive
and false negative rates.
For comparison, two readers manually delineated
FDG-avid lung lesions of diagnosis (Dx) and M6 scans,
based on visual assessment. We also applied different
thresholds for automated segmentation within the lung
mask, namely SUV > 1 and T40%. SUV > 1 is a fixed
threshold, used in previous TB studies [41] to delineate lung
lesions on PET, while T40% refers to 40% of the maximum
intensity in a VOI, previously used in cancer studies [6].
CT density quantification
Concurrently with the PET segmentation and using the
same lung mask, the MATLAB script also segmented the
CT images into five categories based on the density of
each voxel compared to set values obtained from literature
[21, 41]: (1) low density (< − 950 HU), attributed to cavita-
tion or extremely hyper-inflated lung tissue (Vlow); (2) nor-
mal density, between − 950 HU and − 500 HU; (3) soft
lesion volume (Vsoft), from − 500 HU to − 300 HU, usually
tree-in-bud lesions or nodules, but may also include
regular, medium to large vasculature; and (4) medium le-
sion volume (Vmedium) from − 300 HU to − 100 HU. This
category should include very little normal lung tissue and
usually consists of nodular infiltrates, but may also include
hard lesions in early progression or partial resolution; (5)
hard lesion volume (Vhard), above − 100 HU, are usually
due to consolidation, cavity walls, bronchial thickening or
calcified fibrosis.
We performed visual checks of the accuracy of CT
lesion delineation, based on these fixed density
thresholds. For lesions with increased density (Vsoft,
Vmedium, Vhard), the segmented areas corresponded
well to lesion morphology. However, using − 950 HU
as the upper limit for low-density lesions was not
specific enough for cavitation and the segmented
areas in some cases included bullae, bronchiectasis,
and severe emphysema. This necessitated an add-
itional step to measure the volumes of individual
cavities for each scan. This was done using the
MRICro’s 3D region-growing tool (boundary-based
segmentation).
PET lesion intensity quantification
After segmentation, the program quantified the follow-
ing PET parameters: (1) MLV, (2) the mean Z-score in
the MLV (Zmean), (3) TGA (MLV × SUVmean), (4) total
glycolytic activity index (TGAI): the product of the MLV
and mean lesion-to-background intensity (TGAI =
MLV ×mean lesion counts/mean counts in normal lung).
In addition, the program also measured the total lung
volume [TLV (ml)] and the volumes of each abnormal
density category on CT, i.e., Vlow, Vsoft, Vmedium, and
Vhard, as well as a combined PET-CT metric:
MLVabN [the intersection of MLV and area with in-
creased density on CT (≥ 500 HU)].
Re-slicing of the CT to the corresponding PET allowed
the program to compare CT density and PET intensity,
directly per voxel.
Fig. 3 The range, median and 25th and 75th percentiles for percentage of total lung volume classified as FDG avid at different Z-score thresholds
[4–9], in the quantification of PET-CT scans from 15 controls with visually lesion-free lungs
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Manual segmentation
The two manual readers are clinicians, with experi-
ence in the diagnosis and treatment of pulmonary
tuberculosis. They are also clinical trial investigators
and trained in PET-CT evaluation for a phase 3
clinical trial that aims to use PET-CT parameters to guide
TB treatment duration [28]. Manual segmentation of
FDG-avid PET lesions in PTB scans took roughly 30–
90 min per scan.
Statistical analysis
Volumetric comparisons were performed using the dice
similarity coefficient (DSC), a validated approach to
measure spatial overlap [51, 52]. In addition, the true
positive volume fraction (TPFV) was calculated to indi-
cate segmentation sensitivity and one minus the false
positive volume fraction (1-FPVF) to indicate specificity.
Statistical analysis was performed using Statistica Ver-
sion 13©. For numerical variables we report median,
range and 25th and 75th percentiles to accommodate
the modest sample size included in this pilot project.
Agreement measures are reported using a Bland-Altman
plot showing only bias and values and not confidence in-
tervals and standard deviations. We report the correl-
ation coefficient and p values for correlations between
numerical variables.
Results
Application of technique
We successfully implemented the quantification method-
ology in all controls and cases. Creating the masks re-
quired knowledge of lung anatomy, while the other steps
required basic computer literacy. The user input required
for quantification could be divided into (1) file manage-
ment (including the selection, indexing and formatting of
image files) and (2) creating VOIs for lung masks,
background references and areas affected by motion
misregistration. The time required to quantify scans
ranged approximately from 10 min for a lesion-free lung
scan at one time-point, to 45 min for a three time point
series of extensively diseased lungs. Where applicable,
cavity volumes were easily measured with MRICro’s
3D region-growing tool on CT, taking less than
1 min per scan.
The auto-segmented MLV for each scan corresponded
well with visual assessment of the PET scans. No false
positive segmentation was noted on control scans. In the
PTB lung scans, all auto-segmented MLVs corresponded
to areas that appeared FDG avid. No visually FDG-avid
lesions were missed by auto-segmentation.
FDG-avid lesions were also segmented using T40%.
However, when max lesion SUV decreased during treat-
ment, the MLVs became progressively more inclusive
and did not correspond well to visual assessment. As
such, we abandoned T40% as a method to monitor treat-
ment response in a whole lung VOI.
Table 2 shows a summary of DSC values (Table 2),
true positive volume fraction (TPVF; Table 2), 1-false
positive volume fraction (1-FPVF; Table 2), between
readers and automated thresholds at Dx, M6 and com-
bined. Individual segments corresponded better at Dx
Fig. 4 Coronal (left), sagittal (middle) and transverse views of PET
scans of two patients after treatment for pulmonary tuberculosis.
The first patient (a–c) has a residual nodule in the right upper lobe
showing minimally increased FDG avidity. The second patient (d–f)
has a complex lesion in the left upper lobe with mild FDG avidity.
The auto-delineated metabolic lesion volume is overlaid using
ascending Z-score thresholds, respectively at Z = 7 (a, d), Z = 8 (b, e)
and Z = 9 (c, f)
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than M6, independent of which segmentation method
used. DSC between manual and Z-score segmentations
(Z-A to reader A and Z-A to reader B) was slightly lower
than between the manual readers (reader B to reader A),
but higher than DSC between manual and SUV > 1
segmentations. The same trends were noted in regard to
1-FPVF(%) values. In contrast, SUV > 1 segments per-
formed better in regard to TPVF comparison than either
Z-score or manual segmentation. The same behaviour
was also observed when comparing to either unions or
Table 2 Summary of comparisons between independent readers, reader A and reader B, and automated thresholding
segmentations using the Z-score (Z-A and Z-B) and SUV > 1 (SUV). Values for dice similarity coefficient (DSC), true positive volume
fraction (TPVF) and 1 minus false positive volume fraction (1-FPVF) are shown
Dx and M6 Dx M6
Median Range Median Range Median Range
DSC
Z-A to reader A 0.75 0.57–0.91 0.85 0.57–0.91 0.68 0.61–0.84
Z-A to reader B 0.66 0.31–0.94 0.77 0.56–0.94 0.55 0.31–0.79
Z-A to intersection 0.73 0.46–0.89 0.81 0.49–0.89 0.64 0.46–0.78
Z-A to union 0.72 0.30–0.94 0.81 0.63–0.94 0.55 0.30–0.85
SUV to reader A 0.68 0.21–0.90 0.74 0.57–0.90 0.47 0.21–0.77
SUV to reader B 0.63 0.19–0.91 0.75 0.57–0.91 0.45 0.19–0.71
SUV to intersection 0.61 0.11–0.88 0.74 0.50–0.88 0.45 0.11–0.69
SUV to union 0.7 0.18–0.92 0.77 0.64–0.92 0.37 0.18–0.79
Z-A to SUV 0.88 0.15–0.99 0.88 0.75–0.97 0.59 0.15–0.99
Z-B to Z-A 0.83 0.59–0.99 0.89 0.79–0.99 0.63 0.59–0.95
Reader B to A 0.78 0.42–0.92 0.83 0.78–0.92 0.64 0.42–0.85
TPVF (%)
Z-A to reader A 91.4 55.48–100.00 98.9 89.21–100.00 78.5 55.48–93.65
Z-A to reader B 80.5 18.22–99.91 96.3 70.18–99.91 62.0 18.22–94.05
Z-A to intersection 98.0 59.56–100.00 99.9 94.35–100.00 87.5 59.56–98.56
Z-A to union 77.8 17.86–99.92 96.0 70.82–99.92 77.8 17.86–90.34
SUV to reader A 99.4 34.64–100.00 99.8 99.34–100.00 96.6 34.64–100.00
SUV to reader B 92.0 31.92–99.63 96.7 72.27–99.63 84.8 31.92–96.95
SUV to intersection 100.0 53.19–100.00 100.0 99.83–100.00 99.8 53.19–100.00
SUV to union 95.4 24.64–99.91 96.4 73.04–99.91 95.3 24.64–97.28
Z-A to SUV 91.4 17.09–100.00 87.9 59.49–100.00 97.5 17.09–100.00
Z-B to Z-A 92.7 56.35–100.00 86.9 70.80–100.00 100.0 56.35–100.00
Reader B to A 81.4 50.25–98.10 88.5 79.06–98.10 71.1 50.25–93.15
1-FPVF(%)
Z-A to reader A 68.8 40.61–88.04 74.5 40.61–84.70 61.3 55.79–88.04
Z-A to reader B 68.3 31.79–100.00 74.4 39.29–91.24 52.9 31.79–100.00
Z-A to intersection 62.7 30.95–88.04 70.8 32.51–79.93 47.9 30.95–88.04
Z-A to union 75.7 30.54–100.00 88.3 46.25–92.29 62.2 30.54–100.00
SUV to reader A 57.7 11.82–81.57 59.2 39.99–81.57 54.4 11.82–73.02
SUV to reader B 54.6 10.97–85.55 74.6 40.51–85.55 42.8 10.97–70.14
SUV to intersection 48.6 6.10–78.25 58.2 32.94–78.25 30.2 6.10–69.07
SUV to union 66.0 9.91–88.88 75.7 46.85–88.88 55.2 9.91–74.10
Z-A to SUV 100.0 8.36–100.00 100.0 77.01–100.00 100.0 8.36–100.00
Z-B to Z-A 87.3 44.02–100.00 90.3 86.36–100.00 61.5 44.02–89.62
Reader B to A 77.3 26.93–95.40 77.7 65.93–95.40 59.1 26.93–95.32
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the intersections. The DSC between MLV segmented
using the Z-score and the MLV intersection between the
readers was 0.73 (range 0.46–0.94), while the DSC be-
tween the readers’ MLV union was 0.72 (range 0.3–
0.94). The median DSC between the MLV segmented
using SUV > 1 and the readers’ segments intersection
was 0.61 (range 0.11–0.88) and 0.7 (range 0.18–0.92)
when compared to the union of the manual segments.
Inter-user Z-score segmentation (created by different
spheres and lung mask) and inter-reader manual
segmentation showed similar variability at single
time-points, with a median DSC of 0.83 and 0.78 re-
spectively (Table 2). However, there was a much better
agreement in percentage change from diagnosis to M6
for inter-user Z-score segmentation than for manual
inter-reader segmentation. The difference between the
percentage change from Dx to M6 in MLV lesions
volume ranged from − 3.69 to 0.96 for inter-user
Z-scores and − 8.44 to 21.51 for inter-reader MLV
change (Fig. 5).
Z-score segmentation correlated well with SUV > 1 (me-
dian DSC = 0.88). In addition, there was a high correlation
between TGA (product of SUVmean and MLV in SUV > 1)
and TGAI (product of mean lesion-to-background intensity
and MLV in Z-score > 8) across time-points (Dx, M1, M6,
Fig. 6a), which improved when assessing change in inflam-
matory burden over time (Fig. 6b, c).
Response to therapy
Representative quantification patterns of scans from a
control case and PTB patients before, during, and after
treatment, with an overlay of the segmented MLV and a
scatterplot representing the voxels from each scan, are
shown in Fig. 7. The scatter plot of a control scan is
shown in Fig. 7a. The cured patients’ values (Fig. 7b, c)
change toward normal at follow-up, while for the patient
who failed treatment the pattern remains clearly abnor-
mal on the density and intensity axes (Fig. 7d).
Figure 8 demonstrates the dynamics of different scan
parameters during treatment of the five PTB cases, in
relation to clinical outcome. The segmented TGAI
(Fig. 8a) of three out of four cured cases already showed
partial reduction (30–62%) at M1 and continued to de-
crease markedly toward the end of treatment. The fourth
cured patient showed a slight increase by M1, but sig-
nificant reduction by M6. After 6 months of treatment,
all the cured patients showed marked reduction (80–
99%), but only one patient showed nearly complete
metabolic resolution. The patient that failed treatment
remained unchanged over the first month and deterio-
rated by M6. The MLV for this patient (Fig. 8b) showed
very similar patterns during treatment.
The combined lung volume with increased density
(Vsoft + medium + hard) followed a similar trend, although
the decrease from Dx to M6 was less marked (41–
83%) than MLV changes and the failed treatment patient
showed only slightly decreased values from Dx to M6. In
the breakdown of lesions of different density (Fig. 8c–e),
all cured patients showed a marked volume decrease in
hard lesions, already noted by M1 (35–71% reduction)
and continued toward M6 (81–98% reduction). The vol-
umes of medium and soft lesions were more variable,
and a relatively large residual lesion volume was present
at M6 for most cases.
After 1 month of treatment, in cured patients,
MLVabn (Fig. 8f ) decreased modestly in two and
remained stable in the other two. The failed treat-
ment case showed a 13% increase. At M6, however,
all cured cases’ MLVabn had decreased markedly (82–
98%), while the failed treatment case showed a further
increase.
Fig. 5 Bland-Altman plots to show inter-user agreement between
the mean percentage change in metabolic lesion volume from
diagnosis to month 6 of treatment. a Manual segmentation of
reader A and reader B. b Z-score segmentation created using
normal lung and lung masks defined by user A and user B
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Discussion
In this paper, we present a technique to reproducibly quan-
tify pulmonary tuberculosis lesions on PET and CT. We
used patient-specific reference volumes to reduce intra-
and interscan variability on PET and auto-delineation to re-
duce inter-reader and inter-user variability when assessing
multiple widely distributed lesions with complex morph-
ology. The technique quantifies lesions throughout the
lungs in order to measure the central trend of disease
progression or resolution, thus compensating for the vari-
able response of individual lesions during PTB treatment.
The technique introduced some novel concepts in
PET-CT analysis including the use of a patient-specific
reference volume to standardise lung uptake (lesion-to--
background), whole lung automated segmentation of CT
lesions and bivariate quantification of PET and CT im-
ages. It also reapplies concepts previously used in other
settings, such as co-registration of corresponding scans
at different time-points, whole organ (semi-)automated
segmentation of PET uptake, and joint segmentation of
PET and CT [23].
Optimal adaptive thresholds for auto-segmentation of
PET scans were determined using a set of control lung
scans and scans containing lesions with minimal to mildly
increased uptake. Density thresholds for CT scans were de-
termined using values previously reported in literature [41].
We compared the Z-score delineation to manual de-
lineation by two independent readers and a fixed thresh-
old previously used in a TB trial (SUV > 1) [41]. There
was better correlation between the Z-score and manual
segmentation when compared to the fixed threshold.
We also found decreased inter-user variability when
measuring response to treatment when compared to
manual segmentation. However, there was still some
inter-user variability at single time-points, which would
not apply when using a fixed threshold (SUV > 1). Both
automated thresholding techniques saved time and ap-
peared highly sensitive. We also applied a gradient-based
threshold (T40%); however, it did not appear to be ap-
propriate to measure response to treatment in whole
lung VOIs. After treatment, agreement between all
thresholding techniques and readers were lower than
previous reports only focussing on diagnosis [6]. How-
ever, this was expected in highly complex lesions at the
very edge of FDG avidity, found after treatment.
There was good correlation between TGA (based on
mean SUV and volume) and TGAI (normalised to back-
ground lung activity), especially when measuring
changes over time.
We tested whether the technique was accurate enough
to measure changes over time, by applying it to inde-
pendent pilot sets of control cases and PTB cases during
treatment. The quantified variables detected marked
changes within 1 month of treatment. The metrics cor-
responded well with visual scan interpretation, clinical
outcomes and the qualitative classification allocated dur-
ing analysis for the parent study. It also provided a range
of additional information.
Fig. 6 Scatter plots showing correlation between the TGA (based on
SUV and MLV determined by SUV > 1) and TGAI (based on lesion-to-
background ratio and MLV created by Z-score). a Total values at Dx,
M1 and M6. b Percentage change from Dx to M1. c Percentage
change from Dx to M6
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Fig. 7 (See legend on next page.)
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Some challenges and potential drawbacks were encoun-
tered during this pilot application. While using the 3D
region-growing tool in MRIcro was user friendly and eas-
ily reproducible, some manual input was required when
drawing the lung mask, to include dense lesions extending
into the chest wall, and areas of motion misregistration. In
the future, computer-assisted drawing tools or fully
automated lung atlas segmentation and correction of mis-
registration should decrease inter-user variability and time
requirements of any automated technique.
Co-registering baseline and follow-up scans allowed
the user to generate a single-lung mask and reference
volume to use across all time points. This reduced inter-
scan variability and saved time. It did not, however, allow
(See figure on previous page.)
Fig. 7 This shows coronal (left), sagittal (middle) and transverse (right) views of different CT images with the auto-delineated metabolic lesion
volume as an overlay and a scatterplot representing the CT density (Y axis, HU) and the PET uptake intensity (X axis; Z-score) of the voxels held
within the lung mask a Lesion-free lungs from control participant. b–d Dx, M1 and M6 PET-CT scans for PTB patients. b Cured patient with an
improved scan response and moderate uptake still present at M6. c Cured patient, with a resolved scan response. Only minimal intensity residual
lesions and thin-walled cavities still present at M6. d Failed treatment case, with a mixed scan response pattern and multiple lesions with very
high uptake present at M6
Fig. 8 These graphs represent the case-profiles of five different PTB patients and the changes of various auto-segmented PET-CT parameters at
Dx, M1 and M6 (X axis). A straight line represents a cured outcome and the broken line indicates treatment failure. a Total glycolytic activity index.
b Metabolic lesion volume as a percentage of total lung volume. c Vsoft (− 500 HU:− 300 HU) CT lesion volume as a percentage of total lung volume.
d Vmedium (− 300 HU:− 100 HU) CT lesion volume as a percentage of total lung volume. e Vhard (>− 100 HU) CT lesion volume as a percentage of total
lung volume. f Area of lung that shows abnormal density (>− 500 HU) and relative high uptake intensity as a percentage of total lung volume
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for the measurement of changes in total lung volume
over time, which may occur after lesion resolution with
associated fibrosis. Re-slicing allowed direct voxel com-
parison of PET and CT components using a single VOI.
A disadvantage is that there was a smoothing effect on
the CT images. Using a density threshold was not
specific enough to delineate cavity volume, and an add-
itional manual step was required to perform this
function.
Using the mean and standard deviation of reference
volumes to standardise lesion-to-background activity
should decrease interscan and inter-patient variability
compared to techniques that normalise the uptake to
reference volumes from other organs or a theoretical
whole body concentration. Thus, the Z-score takes into
account the variability of FDG uptake in normal lung
tissue and does not depend on dose or weight. The
advantage of the latter is that changes in weight induce
changes in SUV, while not necessarily inducing a change
in FDG uptake.
Semi-automatic delineation of the whole lung allowed
for segmentation of multiple lesions with widespread
distribution and variable intensity, size and morphology.
This shows promise to reduce inter-reader variability,
especially in a self-controlled study measuring changes
after interventions.
Conclusions
This technique to auto-segment and quantify
multi-focal and complex lung lesions on PET and CT
images shows great promise in a pilot set of subjects
and required limited operator input. This study was
only a small pilot study as proof-of-concept. Valid-
ation in a larger cohort, and comparison of scan met-
rics to clinical outcomes and biomarkers is required
to determine indicators of prognosis and cure. Ultim-
ately this methodology, or features thereof, could be
incorporated into standard clinical analysis pipelines
and research protocols.
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